悬吊疗法Neurac技术在脑卒中偏瘫患者康复中的应用

目的 尝试采用悬吊疗法神经肌肉激活（Neurac）技术对脑卒中偏瘫患者进行康复治疗并作为新型康复方 案。方法 选择初次诊断脑卒中偏瘫（Brunnstrom分期Ⅳ~Ⅴ期）患者共81例，根据随机数字表法分为对照组（40例） 和观察组（41例）。对照组采用常规药物治疗和康复训练，观察组同时应用Neurac技术，2组康复训练时间均为每次 50 min，每周 5 次，疗程 4 周。采用 Fugl-Meyer 上肢运动功能评定量表（FMA-UE）、偏瘫上肢功能测试-香港版 （FTHUE-HK）和Barthel指数（BI）评价患者上肢功能恢复情况；Fugl-Meyer下肢运动功能评定量表（FMA-LE）、Berg 平衡量表（BBS）、躯干控制能力评定量表（TCT）以及三维步态训练系统进行步态时空和时相参数分析，评价下肢功 能。结果 治疗后2组FMA-UE、FTHUE-HK和BI评分均较治疗前提高，治疗后观察组各量表评分均明显高于对照 组（P＜0.01）。下肢功能比较发现，治疗后2组FMA-LE、BBS和TCT评分均较治疗前提高，观察组各量表评分均明显 高于对照组（P＜0.05）。治疗后2组步态时空参数中步速、步频和步长均增加，步宽降低，时相参数中双支撑相、健侧 支撑相、患侧支撑相百分比以及健患侧支撑相比值均降低，且观察组改善情况优于对照组（P＜0.05）。结论 Neurac 技术能够进一步改善脑卒中偏瘫患者的上下肢功能，提高肢体平衡和控制能力，改善步态，增强康复质量和生活能 力，有较好的应用推广价值。

Study on the application of Neurac suspension therapy in rehabilitation of stroke patients with hemiplegia

Objective To evaluate the application effect of neuromuscular activation (Neurac) in the rehabilitation of stroke patients with hemiplegia. Methods A total of 81 stroke patients with hemiplegia (Brunnstrom stage Ⅳ-Ⅴ) who were diagnosed in our hospital for the first time were included in this study. Patients were divided into control group (n=40) and observation group (n=41) according to the random number method. The control group was treated with conventional medicine and rehabilitation training, and the observation group was treated with Neurac technique on the basis of the control group. The rehabilitation time of the two groups was 50 minutes each time, 5 times a week for 4 weeks. The scores of Fugl-Meyer upper limb motor function assessment scale (FMA-UE), HongKong version of hemiplegic upper limb function test (FTHUEHK) and Barthel index (BI) were used for the evaluation of the recovery of upper limb function. Fugl-Meyer lower limb motor function assessment scale (FMA-LE), Berg balance scale (BBS), trunk control ability test (TCT), three-dimensional gait training system for gait space-time and phase parameters were used for the evaluation of lower limb function. Results After treatment, the scores of FMA-UE, FTHUE-HK and BI were higher in the two groups than those of before treatment, and the scores were significantly higher in observation group than those of control group (P＜0.01). The FMA-LE, BBS and TCT scores were higher after treatment in the two groups than those of before treatment, and they were significantly higher in observation group than those of control group (P＜0.05). Gait space-time parameters including step speed, stride frequency and step length were increased, while step width was decreased, space-phase parameters including the percentages of double support phase, healthy side support phase, affected side support phase and healthy-affected side support ratio were decreased, and the improvement was better in the observation group than that of the control group (P＜0.05). Conclusion Neurac technology can further improve the upper and lower limb function of stroke patients with hemiplegia, improve the balance and control ability of limbs, improve gait, enhance the quality of rehabilitation and life ability, and has a good application and promotion value.